Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
TGTX
TGTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TGTX News
TG Therapeutics Reports Positive Results for Subcutaneous BRIUMVI
2d ago
stocktwits
Trump's New Attacks on Iran Drive Oil Prices Up
Jun 11 2026
Yahoo Finance
Stock Market Volatility Driven by AI Fears and Trump's Iran Threats
Jun 09 2026
Yahoo Finance
TG Therapeutics Reports Positive Early Results for BRIUMVI in Myasthenia Gravis
Jun 09 2026
stocktwits
TG Therapeutics Reports Positive Phase 1 Data for BRIUMVI in Myasthenia Gravis
Jun 09 2026
NASDAQ.COM
TG Therapeutics Initiates Pivotal Mid-Stage Trial for Briumvi in Myasthenia Gravis
Jun 09 2026
seekingalpha
BRIUMVI Shows Positive Phase 1 Results in Myasthenia Gravis Trial
Jun 09 2026
Newsfilter
Broadcom and CrowdStrike Shares Drop Post Earnings
Jun 04 2026
Yahoo Finance
TG Therapeutics Shares Rise 10% on Positive Trial Data for Briumvi
Jun 03 2026
seekingalpha
TG Therapeutics Reports Positive Clinical Data for Briumvi Injectable Formulation
Jun 03 2026
stocktwits
Positive Progress in BRIUMVI Subcutaneous Dosing Study
Jun 03 2026
Newsfilter
BRIUMVI Significantly Reduces Relapse Rate in Treatment-Naïve Patients
Jun 01 2026
Newsfilter
TG Therapeutics CEO to Attend Healthcare Conference
May 28 2026
Newsfilter
TG Therapeutics Reports Positive Phase 3 Results for BRIUMVI in MS Treatment
May 27 2026
NASDAQ.COM
TG Therapeutics ENHANCE Trial Achieves Primary Endpoint
May 27 2026
seekingalpha
TG Therapeutics Reports Positive Phase 3 ENHANCE Trial Results for BRIUMVI
May 27 2026
Newsfilter
Show More News
